Paper
Freshwater spongeThird-party product study
DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial
This is a clinical study of another company's product. It is not a result obtained with UNIZ LAB products.
- Clinical Trials
- 2023
Key Summary (10 Points)
- 1
This study was a 12-week randomized, double-blind, placebo-controlled clinical trial involving 181 acne patients (91 in DMT310 group, 90 in placebo group).
- 2
DMT310 is a natural-based topical formulation applied once weekly, developed to address the problem of poor patient adherence with traditional acne medications.
- 3
The DMT310 group demonstrated statistically significant reduction in inflammatory lesion counts compared to placebo at all time points (week 12: -15.64 vs -10.84, P<0.001).
- 4
DMT310 treatment was also more effective at reducing noninflammatory lesions than placebo (week 12: -18.26 vs -12.41, P<0.001).
- 5
Success rates on Investigator's Global Assessment were consistently higher in the DMT310 group than placebo across all time points (week 12: 44.40% vs 17.78%, P<0.001).
- 6
No serious treatment-related adverse events occurred in the DMT310 group, demonstrating excellent safety and tolerability profiles.
- 7
The once-weekly application schedule offers significant clinical advantages over daily treatments by substantially improving patient medication adherence.
- 8
The multicenter design involving patients 12 years and older enhances the credibility and generalizability of the trial results.
- 9
DMT310 demonstrated comprehensive therapeutic effects by simultaneously reducing both inflammatory and noninflammatory lesions.
- 10
These findings establish DMT310 as a valuable new treatment option for patients with moderate-to-severe acne.
Abstract
Reproduced verbatim from the source. Use the link above to read the full text.
Poor patient adherence with antiacne medications is a common clinical challenge. DMT310, a natural, topical product with a once-weekly application schedule, may alleviate this obstacle. Evaluate the safety, tolerability, and efficacy of DMT310 in treating moderate-to-severe acne. This 12-week, randomized, double-blind, placebo-controlled, multicenter clinical trial enrolled participants 12 years and older with moderate-to-severe acne. The intent-to-treat population included a total of 181 participants (DMT310, N = 91; placebo, N = 90). Participants who received DMT310 vs participants treated with placebo demonstrated a statistically significant greater reduction in the number of inflammatory and noninflammatory lesions at all time points: inflammatory lesion counts at week 12 (-15.64 vs -10.84, P < .001); noninflammatory lesion counts at week 12 (-18.26 vs -12.41, P < .001). DMT310-treated participants also had higher rates of Investigator's Global Assessment treatment success than participants in the placebo group at all time points: Investigator's Global Assessment at week 12 (44.40% vs 17.78%; P < .001). No serious treatment related adverse events occurred. DMT310 once-weekly topical treatment significantly reduced both inflammatory and noninflammatory lesions and yielded a greater proportion of Investigator's Global Assessment treatment success at all time points in participants with moderate-to-severe acne.
Keywords
Citation
Eichenfield L, DuBois J, Gold M, Nardo C, Draelos Z (2023). DMT310, a novel once-weekly topical treatment for patients with moderate-to-severe acne vulgaris: Results of a phase 2b randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2023.05.070